温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.ft.com/biotech
点击访问原文链接

Biotech | Financial Times

进入原网站 导航首页
Accessibility helpSign InSubscribeFinancial TimesSubscribeSign InHomeWorldWorld HomeMiddle East warGlobal EconomyUKUSChinaAfricaAsia PacificEmerging MarketsEuropeWar in UkraineAmericasMiddle East & North AfricaThe hunt for Iran’s ballistic missile crewsAmerica chose this war — and must now choose how to end itThe guards rise again: the force still shaping IranSwitzerland votes to end ‘marriage penalty’ in historic tax referendumMuscat airport limits private jet flights as wealthy leave the GulfUSUS HomeUS EconomyUS CompaniesUS Politics & PolicyAmerica chose this war — and must now choose how to end itTrump raises the stakes in Iran by weighing deployment of US ground forcesChina signals it wants a Trump visit despite Iran warLiberals should be less shy about saying what they stand forDonald Trump calls for more US military action in Latin AmericaCompaniesCompanies HomeEnergyFinancialsHealthIndustrialsMediaProfessional ServicesRetail & ConsumerTech SectorTelecomsTransportMuscat airport limits private jet flights as wealthy leave the GulfOil surges past $100 a barrel for the first time in four yearsIn the centre of the storm: what does the Iran war mean for Dubai?Liberals should be less shy about saying what they stand forKKR eyes multibillion-dollar sale of data centre cooling companyTechTech HomeArtificial intelligenceSemiconductorsCyber SecuritySocial MediaKKR eyes multibillion-dollar sale of data centre cooling companySamsung seeks AI deals to challenge Apple’s smartphone leadPalmer Luckey’s $1bn pitch to reboot 1990s video game consolesGoogle gives CEO Sundar Pichai new pay deal worth up to $692mnUS draws up strict new AI guidelines amid Anthropic clashMarketsMarkets HomeAlphavilleMarkets DataCryptoCapital MarketsCommoditiesCurrenciesEquitiesMonetary Policy RadarWealth ManagementMoral MoneyETF HubFund ManagementTradingOil surges past $100 a barrel for the first time in four yearsIs the nightmare scenario for global energy here?US faced with few good options to tamp down surging oil pricesBritain is now the home of the Middle ManInvestors are not ready for a true shockClimateOpinionOpinion HomeColumnistsThe FT ViewThe Big ReadLexObituariesLettersAmerica chose this war — and must now choose how to end itWe’ll always have DubaiLiberals should be less shy about saying what they stand forThe war of unintended consequencesEurope’s impotence extends to energyLexWork & CareersWork & Careers HomeBusiness School RankingsBusiness EducationEurope's Start-Up HubsEntrepreneurshipRecruitmentBusiness BooksBusiness TravelWorking ItWhy it’s time to end the grim march of the touchscreenGoogle gives CEO Sundar Pichai new pay deal worth up to $692mnPapier founder: ‘I don’t own stocks or shares — it’s too much risk’Life & ArtsLife & Arts HomeArtsBooksFood & DrinkFT MagazineHouse & HomeStylePuzzlesTravelFT GlobetrotterWe’ll always have DubaiTrump’s war on Iran is spreading. Where does it stop?The curse of the ancient lead tabletsPalmer Luckey’s $1bn pitch to reboot 1990s video game consolesThe real-world paths to hellHow To Spend ItHomeWorldUSCompaniesTechMarketsClimateOpinionLexWork & CareersLife & ArtsHow To Spend ItFinancial TimesSubscribeSign InZealand Pharma ASBiotech group’s shares hit by weight-loss drug setbackZealand Pharma falls 34% following mid-stage trial results for treatment being developed with RochePharmaceuticals sectorGSK secures potential ‘multi-blockbuster’ drug in $950mn dealNew chief Luke Miels swoops on Canada’s 35Pharma in push to replenish pipeline and boost revenuesMergers & AcquisitionsLex. Why 2026 will be a blockbuster year for biotech M&ABig pharma has emerged from its 2025 paralysis with plenty of firepowerUS companiesMerck splits operations to separate oncology from non-cancer drugsReshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment KeytrudaDisease control and preventionTrump administration reverses move to block Moderna flu vaccine trialU-turn comes after backlash from the company and US biotech industryUS companiesDanaher strikes $10bn deal for medical device maker MasimoAcquisition by US life sciences manufacturer makes it a market leader in production of pulse oximetersScienceUK biotech keeps selling itself to AmericaA shortage of late-stage capital pushes the biggest prizes into US handsDrugs researchChina’s labs pull ahead as global drugmakers invest in biotech pioneersFaster trials and lower costs are drawing western multinationals as they seek new treatmentsMergers & AcquisitionsGSK to buy US biotech behind food allergy drug for $2.2bnBig pharma groups look to boost line-up as they confront patent cliff for blockbuster treatmentsPharmaceuticals sectorMerck in talks to buy cancer drugmaker Revolution Medicines for up to $32bnUS company is attempting to acquire the maker of a new treatment for pancreatic cancerHealthAmgen swoops on UK cancer biotech in deal worth up to $840mnDark Blue Therapeutics was spun out of an Oxford university incubator in 2022Drugs researchPrices for lab monkeys surge on China biotech boomMore drugs entering middle or late-stage development drive up demandUS companiesThe billionaire ex-Enron trader trying to upend US drug policyJohn Arnold parlayed windfall from natural gas bets into a foundation that is challenging medicine approvalsLife & ArtsFT Magazine. Jailed for gene-editing, a notorious scientist is not done yetHe Jiankui’s experiment with human embryos caused global outrage. Can he make an unlikely comeback?Zealand Pharma ASBiotech boss urges pharma to move on from ‘weight-loss Olympics’Zealand Pharma chief says next-generation obesity drugs will need to be longer lasting and better toleratedSpecial ReportFT Health: Communicable DiseasesTuberculosis rethink; fears for HIV progress; AI potential against resistant bacteria; UK boosts wastewater tests; rebuilding immunity to superbugs; insect-borne diseases threat; Chagas disease explainerUS companiesBiotech rally mints huge profits for hedge fundsWave of M&A fuels rally as big pharma groups hunt for blockbusters ahead of patent cliffGenomicsLab-grown genomes set to transform human DNAResearch shows synthetic chromosomes can be transferred to human cells with potential to improve viral resistanceFT News Briefing podcastAI chatbot race enters crunch phaseSam Altman declares ‘code red’ as global rivals and new AI entrants narrow OpenAI’s early leadDrugs researchThe Big Read. Will the next blockbuster drug come from China?The biopharma industry is booming following record investment and improved supply chainsArtificial intelligenceNew AI model enhances diagnosis of rare diseasesPopEVE system outperformed rivals such as Google DeepMind’s AlphaMissenseModernaModerna is most shorted stock in S&P 500 as Americans skip jabsMaker of Covid-19 shots has slumped since pandemic as people turn against vaccinesMedical scienceNeglecting infectious diseases is a market failureMajor companies are reducing research on new medicines for illnesses that affect billions of peopleMichelle ChildsJohnson & Johnson Co IncJ&J buys cancer drugmaker for $3bn in latest biotech dealPharma group hopes acquisition will help to offset losses from expiring patents on blockbuster drugsMerck & Co IncMerck agrees $9.2bn deal for flu-prevention biotech CidaraBidding war goes down to wire for company whose lead drug is potential alternative to vaccines for vulnerable patientsJoin us at an FT Live eventFT LiveUS Pharma and Biotech SummitFT LiveGlobal Pharma and Biotech SummitExplore all eventsHelp CentreContact UsAbout UsAccessibilityCareersSuppliersTerms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & PoliciesShare News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT SchoolsPortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency ConverterFT Live EventsFT ForumsFT Leaders AcademyMore from the FT GroupFT Editorial Code of PracticeUKSubscribe for full accessHomeWorldMiddle East warGlobal EconomyUKUSChinaAfricaAsia PacificEmerging MarketsEuropeWar in UkraineAmericasMiddle East & North AfricaUSUS EconomyUS CompaniesUS Politics & PolicyCompaniesEnergyFinancialsHealthIndustrialsMediaProfessional ServicesRetail & ConsumerTech SectorTelecomsTransportTechArtificial intelligenceSemiconductorsCyber SecuritySocial MediaMarketsAlphavilleMarkets DataCryptoCapital MarketsCommoditiesCurrenciesEquitiesMonetary Policy RadarWealth ManagementMoral MoneyETF HubFund ManagementTradingClimateOpinionColumnistsThe FT ViewThe Big ReadLexObituariesLettersLexWork & CareersBusiness School RankingsBusiness EducationEurope's Start-Up HubsEntrepreneurshipRecruitmentBusiness BooksBusiness TravelWorking ItLife & ArtsArtsBooksFood & DrinkFT MagazineHouse & HomeStylePuzzlesTravelFT GlobetrotterPersonal FinanceProperty & MortgagesInvestmentsPensionsTaxBanking & SavingsAdvice & CommentHow To Spend ItSpecial ReportsAlphavilleFT EditLunch with the FTFT Globetrotter#techAsiaMoral MoneyVisual and data journalismNewslettersVideoPodcastsNews feedFT SchoolsFT Live EventsFT ForumsFT Leaders AcademymyFTPortfolioFT Digital EditionCrosswordOur AppsHelp CentreSubscribeSign In

智能索引记录